Drazan D, Czajka H, Maguire JD, Pregaldien JL, et al. A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults. Vaccine 2022;40:351-358.
PMID: 34961633